Category: BioTech
The analysis published under this category are as follows.
Tuesday, February 01, 2022
Unloved Biotech Stocks Sector / Companies / BioTech
By: Nadeem_Walayat
And the same it true for the unloved Biotech sector, where here's a taste of what to expect when I take a detail look at the biotech stocks. It's definitely going to take something special to buck the sector downtrend!
Read full article... Read full article...
Friday, November 05, 2021
Breakthrough Tech Could Give Billions Access To Healthcare / Companies / BioTech
By: Submissions
There’s a massive announcement set to take place later this year, and it could change the $12 trillion healthcare industry forever.
Over the last 2 years, we’ve seen a huge transformation as businesses across nearly every industry have gone digital.
And with the health crisis sweeping the globe last year, the healthcare sector was no different.
Read full article... Read full article...
Wednesday, November 03, 2021
The No.1 Biotech Stock Of 2021? / Companies / BioTech
By: Submissions
It’s an industry that will never retire or ever go obsolete.
It’s a revolutionary virtual marketplace, and it’s one of the fastest-growing markets on the planet.
The world has gone full-on mobile, and nothing is nothing anymore without an app.
The global mobile app sector generated over $365 billion in revenue in 2018 …
In just a year-and-a-half, it will exceed $935 billion in revenue via paid downloads and in-app advertising.
But more importantly, investing in early-stage app development can be one of the quickest ways to make 10X…20X...50X...and even 100X returns on your investment.
Read full article... Read full article...
Tuesday, October 19, 2021
The Most Exciting Medical Breakthrough Of The Decade? / Companies / BioTech
By: OilPrice_Com
According to Google’s Health boss David Feinberg... over one billion people a day search Google for health concerns.But, what if, instead... they could "consult" a phone app with the power of hundreds of doctors?
That's exactly what will be available weeks from now when Treatment.com’s (CSE: TRUE; OTC: TREIF) and their big tech platform for healthcare, deliver the breakthrough AI app Cara launches.
After five years in beta, we think that they are about to disrupt the $11.8 trillion healthcare industry.
Read full article... Read full article...
Monday, October 18, 2021
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector / Companies / BioTech
By: OilPrice_Com
A massive disruption now appears imminent in one of the world’s largest – and most important – industries.
In much the same way that Amazon disrupted the retail business – and how PayPal disrupted the payments industry – one under-the-radar health technology company now seeks to transform the $11.85 trillion global health industry.
By moving healthcare away from brick and mortar, traditional medicine into an AI-driven tool that offers unprecedented speed, efficiency, and accuracy...
Monday, October 04, 2021
Chasing Value with Five More Biotech Stocks for the Long-run / Companies / BioTech
By: Nadeem_Walayat
Five more biotech stocks to add to the strategy of invest and forget for a potential X10 return. a reminder of why I am engaging in this binge on biotech stocks after having been focused on AI stocks for the past 5 years.
1. Biotech stocks are an unloved stocks sector whilst tech stocks over valued, even the ultra safe stocks such as the Top 10, so I am reluctant to add at current valuations hence why I hit the SELL button for the first time in many years and reduced my exposure to AI stocks by about 40%.
2. That biotech is a derivative of AI, we'll most sectors will soon become a derivative of AI because it is the PRIMARY tech megatrend of our age that will continue to broaden its reach to encompass all sectors of the economy.
Read full article... Read full article...
Sunday, October 03, 2021
Aptorum Group - APM - High RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run / Companies / BioTech
By: Nadeem_Walayat
Five more biotech stocks to add to the strategy of invest and forget for a potential X10 return. a reminder of why I am engaging in this binge on biotech stocks after having been focused on AI stocks for the past 5 years.
1. Biotech stocks are an unloved stocks sector whilst tech stocks over valued, even the ultra safe stocks such as the Top 10, so I am reluctant to add at current valuations hence why I hit the SELL button for the first time in many years and reduced my exposure to AI stocks by about 40%.
2. That biotech is a derivative of AI, we'll most sectors will soon become a derivative of AI because it is the PRIMARY tech megatrend of our age that will continue to broaden its reach to encompass all sectors of the economy.
3. That one of my former biotech 12xers got taken over (GW Pharma) that flooded my account with cash early May and so that focused my attention on repopulating my portfolio with 10 more biotech stocks where I expect at least 3 to 10x, with most of the rest expected to survive to varying extent. Though this is the stock market and so there are never any guarantees especially where such smallish cap stocks are concerned.
Read full article... Read full article...
Thursday, September 30, 2021
BioDelivery Sciences International - BDSI - High RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run / Companies / BioTech
By: Nadeem_Walayat
Five more biotech stocks to add to the strategy of invest and forget for a potential X10 return. a reminder of why I am engaging in this binge on biotech stocks after having been focused on AI stocks for the past 5 years.
1. Biotech stocks are an unloved stocks sector whilst tech stocks over valued, even the ultra safe stocks such as the Top 10, so I am reluctant to add at current valuations hence why I hit the SELL button for the first time in many years and reduced my exposure to AI stocks by about 40%.
2. That biotech is a derivative of AI, we'll most sectors will soon become a derivative of AI because it is the PRIMARY tech megatrend of our age that will continue to broaden its reach to encompass all sectors of the economy.
3. That one of my former biotech 12xers got taken over (GW Pharma) that flooded my account with cash early May and so that focused my attention on repopulating my portfolio with 10 more biotech stocks where I expect at least 3 to 10x, with most of the rest expected to survive to varying extent. Though this is the stock market and so there are never any guarantees especially where such smallish cap stocks are concerned.
Read full article... Read full article...
Wednesday, September 29, 2021
Takeda - TAK - High RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run / Companies / BioTech
By: Nadeem_Walayat
Five more biotech stocks to add to the strategy of invest and forget for a potential X10 return. a reminder of why I am engaging in this binge on biotech stocks after having been focused on AI stocks for the past 5 years.
1. Biotech stocks are an unloved stocks sector whilst tech stocks over valued, even the ultra safe stocks such as the Top 10, so I am reluctant to add at current valuations hence why I hit the SELL button for the first time in many years and reduced my exposure to AI stocks by about 40%.
2. That biotech is a derivative of AI, we'll most sectors will soon become a derivative of AI because it is the PRIMARY tech megatrend of our age that will continue to broaden its reach to encompass all sectors of the economy.
3. That one of my former biotech 12xers got taken over (GW Pharma) that flooded my account with cash early May and so that focused my attention on repopulating my portfolio with 10 more biotech stocks where I expect at least 3 to 10x, with most of the rest expected to survive to varying extent. Though this is the stock market and so there are never any guarantees especially where such smallish cap stocks are concerned.
Read full article... Read full article...
Tuesday, September 28, 2021
Cara Therapeutics - CARA - High RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run / Companies / BioTech
By: Nadeem_Walayat
Five more biotech stocks to add to the strategy of invest and forget for a potential X10 return. a reminder of why I am engaging in this binge on biotech stocks after having been focused on AI stocks for the past 5 years.
1. Biotech stocks are an unloved stocks sector whilst tech stocks over valued, even the ultra safe stocks such as the Top 10, so I am reluctant to add at current valuations hence why I hit the SELL button for the first time in many years and reduced my exposure to AI stocks by about 40%.
2. That biotech is a derivative of AI, we'll most sectors will soon become a derivative of AI because it is the PRIMARY tech megatrend of our age that will continue to broaden its reach to encompass all sectors of the economy.
3. That one of my former biotech 12xers got taken over (GW Pharma) that flooded my account with cash early May and so that focused my attention on repopulating my portfolio with 10 more biotech stocks where I expect at least 3 to 10x, with most of the rest expected to survive to varying extent. Though this is the stock market and so there are never any guarantees especially where such smallish cap stocks are concerned.
Read full article... Read full article...
Monday, September 27, 2021
Blueprint Medicines - BPMC - High RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run / Companies / BioTech
By: Nadeem_Walayat
Five more biotech stocks to add to the strategy of invest and forget for a potential X10 return. a reminder of why I am engaging in this binge on biotech stocks after having been focused on AI stocks for the past 5 years.
1. Biotech stocks are an unloved stocks sector whilst tech stocks over valued, even the ultra safe stocks such as the Top 10, so I am reluctant to add at current valuations hence why I hit the SELL button for the first time in many years and reduced my exposure to AI stocks by about 40%.
2. That biotech is a derivative of AI, we'll most sectors will soon become a derivative of AI because it is the PRIMARY tech megatrend of our age that will continue to broaden its reach to encompass all sectors of the economy.
3. That one of my former biotech 12xers got taken over (GW Pharma) that flooded my account with cash early May and so that focused my attention on repopulating my portfolio with 10 more biotech stocks where I expect at least 3 to 10x, with most of the rest expected to survive to varying extent. Though this is the stock market and so there are never any guarantees especially where such smallish cap stocks are concerned.
Read full article... Read full article...
Tuesday, July 27, 2021
Chasing Value in Unloved by Markets Small Cap Biotech Stocks for the Long-run / Companies / BioTech
By: Nadeem_Walayat
Five more biotech stocks to add to the strategy of invest and forget for a potential X10 return. a reminder of why I am engaging in this binge on biotech stocks after having been focused on AI stocks for the past 5 years.
1. Biotech stocks are an unloved stocks sector whilst tech stocks over valued, even the ultra safe stocks such as the Top 10, so I am reluctant to add at current valuations hence why I hit the SELL button for the first time in many years and reduced my exposure to AI stocks by about 40%.
2. That biotech is a derivative of AI, we'll most sectors will soon become a derivative of AI because it is the PRIMARY tech megatrend of our age that will continue to broaden its reach to encompass all sectors of the economy.
Read full article... Read full article...
Sunday, July 04, 2021
Atea Pharmaceuticals - AVIR - X10 Stock for Max Risk / Companies / BioTech
By: Nadeem_Walayat
Life Sciences Biotech Smaller Cap High Risk Stocks Investing Binge
Why has my focus shifted to biotech stocks and not more tech stocks?
Firstly, I have been investing in biotech stocks for DECADES, it's just that since 2015 my focus shifted to the emerging AI mega-trend to make sure I was invested to capitalise on a trend that was clear to me would span DECADES, at the time I thought I was probably getting in late on the AI Mega-trend but clearly that is always the case! WE ALWAYS THINK we're late to the party but this trend is going to run right into the end of the 2030's
This also explains why I hold the likes of GSK and JNJ amongst a string of smaller cap biotech stocks many of which have been disappearing from my portfolio over the years usually due to being taken over as it looks likely to be the case for GW Pharma later this year. So I need to replenish this once much loved and now neglected stock sector with a string of new smaller cap high risk stocks for the next 5 to 10 years.
Read full article... Read full article...
Saturday, July 03, 2021
Neurocrine Biosciences - NBIX - Low Risk Biotech X10 Stock / Companies / BioTech
By: Nadeem_Walayat
Life Sciences Biotech Smaller Cap High Risk Stocks Investing Binge
Why has my focus shifted to biotech stocks and not more tech stocks?
Firstly, I have been investing in biotech stocks for DECADES, it's just that since 2015 my focus shifted to the emerging AI mega-trend to make sure I was invested to capitalise on a trend that was clear to me would span DECADES, at the time I thought I was probably getting in late on the AI Mega-trend but clearly that is always the case! WE ALWAYS THINK we're late to the party but this trend is going to run right into the end of the 2030's
This also explains why I hold the likes of GSK and JNJ amongst a string of smaller cap biotech stocks many of which have been disappearing from my portfolio over the years usually due to being taken over as it looks likely to be the case for GW Pharma later this year. So I need to replenish this once much loved and now neglected stock sector with a string of new smaller cap high risk stocks for the next 5 to 10 years.
Secondly, our beloved AI stocks have been BID UP to high valuations, yes including Google, so they are not CHEAP, even after a 10% to 15% correction i.e. the likes of Microsoft and Amazon are discounting a lot of future earnings growth! Of course that does not necessarily mean that they are about to fall to what I would consider to be fair value let lone cheap levels as they did during March 2020 because at the end of the day they are GOOD stocks so usually command a healthy premium to invest in.
Read full article... Read full article...
Friday, July 02, 2021
CRISPR - CRSP - GENE EDITING Stock Analysis - Risk Level 9 / Companies / BioTech
By: Nadeem_Walayat
Life Sciences Biotech Smaller Cap High Risk Stocks Investing Binge
Why has my focus shifted to biotech stocks and not more tech stocks?
Firstly, I have been investing in biotech stocks for DECADES, it's just that since 2015 my focus shifted to the emerging AI mega-trend to make sure I was invested to capitalise on a trend that was clear to me would span DECADES, at the time I thought I was probably getting in late on the AI Mega-trend but clearly that is always the case! WE ALWAYS THINK we're late to the party but this trend is going to run right into the end of the 2030's
This also explains why I hold the likes of GSK and JNJ amongst a string of smaller cap biotech stocks many of which have been disappearing from my portfolio over the years usually due to being taken over as it looks likely to be the case for GW Pharma later this year. So I need to replenish this once much loved and now neglected stock sector with a string of new smaller cap high risk stocks for the next 5 to 10 years.
Read full article... Read full article...
Thursday, July 01, 2021
ABBVIE - ABBV 116 - Cheap Low Risk Pharma Stock Investing - Risk 1 / Companies / BioTech
By: Nadeem_Walayat
Life Sciences Biotech Smaller Cap High Risk Stocks Investing Binge
Why has my focus shifted to biotech stocks and not more tech stocks?
Firstly, I have been investing in biotech stocks for DECADES, it's just that since 2015 my focus shifted to the emerging AI mega-trend to make sure I was invested to capitalise on a trend that was clear to me would span DECADES, at the time I thought I was probably getting in late on the AI Mega-trend but clearly that is always the case! WE ALWAYS THINK we're late to the party but this trend is going to run right into the end of the 2030's
This also explains why I hold the likes of GSK and JNJ amongst a string of smaller cap biotech stocks many of which have been disappearing from my portfolio over the years usually due to being taken over as it looks likely to be the case for GW Pharma later this year. So I need to replenish this once much loved and now neglected stock sector with a string of new smaller cap high risk stocks for the next 5 to 10 years.
Secondly, our beloved AI stocks have been BID UP to high valuations, yes including Google, so they are not CHEAP, even after a 10% to 15% correction i.e. the likes of Microsoft and Amazon are discounting a lot of future earnings growth! Of course that does not necessarily mean that they are about to fall to what I would consider to be fair value let lone cheap levels as they did during March 2020 because at the end of the day they are GOOD stocks so usually command a healthy premium to invest in.
Read full article... Read full article...
Thursday, June 24, 2021
Life Sciences Biotech Smaller Cap High Risk Stocks Investing Binge / Companies / BioTech
By: Nadeem_Walayat
Why has my focus shifted to biotech stocks and not more tech stocks?
Firstly, I have been investing in biotech stocks for DECADES, it's just that since 2015 my focus shifted to the emerging AI mega-trend to make sure I was invested to capitalise on a trend that was clear to me would span DECADES, at the time I thought I was probably getting in late on the AI Mega-trend but clearly that is always the case! WE ALWAYS THINK we're late to the party but this trend is going to run right into the end of the 2030's
Read full article... Read full article...
Friday, June 11, 2021
Big Pharma Is Back! Biotech Skyrockets On Biogen’s New Alzheimer Drug Approval / Companies / BioTech
By: Chris_Vermeulen
The FDA issued an accelerated approval status for Biogen’s new Alzheimer drug with specific requirements related to consumer use and results. In these cases, the FDA is allowing Biogen to move into a more open consumer trial where the results and side-effects of this new drug will be identified fairly quickly.
This new drug targets the plague in the heart and brain that is associated with Alzheimer’s. Over five million Americans live with some form of Alzheimer’s currently. The Alzheimers Association continues to provide detailed statistics related to how this disease relates to various segments of American society. You can read more about how big this announcement is in terms of how Alzheimer’s affects Americans in this 2019 Alzheimer’s Disease Facts And Figures report.
This news of a new Biogen Alzheimer’s drug has sent XBI skyrocketing – yet the news may not be enough to continue to trend across an entire market sector. The one thing that I would like to point out is that news of a single drug that has entered early-stage accelerated approval by the FDA does not make a new trend – it makes a news blip.
Read full article... Read full article...
Friday, May 21, 2021
3 World-Shaking Trends Investors Need To Watch This Year / Companies / BioTech
By: FinancialMorningPost
...
Thursday, May 20, 2021
Is This The Most Exciting Healthcare Development Of The Year? / Companies / BioTech
By: FinancialMorningPost
...